SPY319.34+7.98 2.56%
DIA271.54+8.21 3.12%
IXIC9,814.08+198.27 2.06%

Needham Maintains Buy on Aeglea BioTherapeutics, Lowers Price Target to $11

Needham analyst Chad Messer maintains Aeglea BioTherapeutics (NASDAQ:AGLE) with a Buy and lowers the price target from $14 to $11.

Benzinga · 05/07/2020 18:07

Needham analyst Chad Messer maintains Aeglea BioTherapeutics (NASDAQ:AGLE) with a Buy and lowers the price target from $14 to $11.